Non-surgical treatments for basal cell skin cancer

封面

如何引用文章

全文:

详细

Basal cell carcinoma is the most common nonmelanoma skin cancer. It originates from undifferentiated cells in the basal cell layer of the epidermis or from the outer root sheath of the hair follicle. The most important factor in development of basalioma is ultraviolet radiation. Surgery is considered the gold standard of treatment for basal cell cancer. However, nonsurgical options are available for individuals who are unsuitable for surgery. The purpose of this review is to summarize the efficacy and indications of alternative, nonsurgical treatments that can be used in the management of basal cell cancer

Effective nonsurgical treatments include destructive methods (eg, curettage and electrodessication, cryosurgery, laser), photodynamic therapy, topical medications, hedgehog pathway inhibitors. Nonsurgical therapeutic alternatives are safe and effective for the treatment of BCC. Factors such as tumor location, size, and histopathological subtype should be taken into consideration when selecting optimal treatment, cosmetic results and patient preference should be considered too.

To search for the necessary literature, the PubMed, MedLine, Web of Science and RSCI databases were used.

作者简介

Alexey Kubanov

State Research Center of Dermatovenereology and Cosmetology

Email: alex@cnikvi.ru
ORCID iD: 0000-0002-7625-0503
SPIN 代码: 8771-4990

MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences

俄罗斯联邦, Korolenko str., 3, bldg 6, 107076, Moscow

Rifat Saytburkhanov

State Research Center of Dermatovenereology and Cosmetology

编辑信件的主要联系方式.
Email: rifat03@yandex.ru
ORCID iD: 0000-0001-6132-5632
SPIN 代码: 1149-2097

dermatovenereologist

俄罗斯联邦, Korolenko str., 3, bldg 6, 107076, Moscow

Xenia Plakhova

State Research Center of Dermatovenereology and Cosmetology

Email: plahova@cnikvi.ru
ORCID iD: 0000-0003-4169-4128
SPIN 代码: 7634-5521

MD, Dr. Sci. (Med.)

俄罗斯联邦, Korolenko str., 3, bldg 6, 107076, Moscow

Irina Kondrakhina

State Research Center of Dermatovenereology and Cosmetology

Email: kondrakhina77@gmail.com
ORCID iD: 0000-0003-3662-9954
SPIN 代码: 8721-9424

MD, Cand. (Sci.) Med.

俄罗斯联邦, Korolenko str., 3, bldg 6, 107076, Moscow

参考

  1. Prieto-Granada C, Rodriguez-Waitkus P. Basal cell carcinoma: Epidemiology, clinical and histologic features, and basic science overview. Curr Probl Cancer. 2015;39(4):198–205. doi: 10.1016/j.currproblcancer.2015.07.004
  2. Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015;88(2):167–179.
  3. Zanetti R, Rosso S, Martinez C, Nieto A, Miranda A, Mercier M, et al. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer. 2006;94(5):743–751. doi: 10.1038/sj.bjc.6602982
  4. Correia de Sá TR, Silva R, Lopes JM. Basal cell carcinoma of the skin (part 1): epidemiology, pathology and genetic syndromes. Future Oncol. 2015;11(22):3011–3021. doi: 10.2217/fon.15.246
  5. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–1217. doi: 10.1016/j.cell.2013.05.039
  6. Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, Marks GC, Gaffney P, Battistutta D, Frost C, Lang C, Russell A. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet. 1999;354(9180):723–729. doi: 10.1016/S0140-6736(98)12168-2
  7. Ulrich C, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, Eberle J, Terhorst D, Sterry W, Stockfleth E. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161 Suppl 3:78–84. doi: 10.1111/j.1365-2133.2009.09453.x
  8. Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). — 2020. [Kaprin AD, Starinskij VV, Shahzadova AO. Zlokachestvennye novoobrazovanija v Rossii v 2019 godu (zabolevaemost' i smertnost'). — 2020 (In Russ.)]
  9. Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches. Dermatol Ther (Heidelb). 2017;7(Suppl 1):5–19. doi: 10.1007/s13555-016-0165-y
  10. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol. 2002;147(1):41–47. doi: 10.1046/j.1365-2133.2002.04804.x
  11. Gandhi SA, Kampp J. Skin Cancer Epidemiology, Detection, and Management. Med Clin North Am. 2015;99(6):1323–1335. doi: 10.1016/j.mcna.2015.06.002
  12. McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma. A possible indicator of differing causes. Arch Dermatol. 1997;133(5):593–596.
  13. Цветкова Г.М., Мордовцева В.В., Вавилов А.М., Мордовцев В.Н. (2003). Патоморфология болезней кожи. М.: Медицина. [Cvetkova GM, Mordovceva VV, Vavilov AM, Mordovcev VN. (2003). Patomorfologija boleznej kozhi. Moscow: Medicina (In Russ.)]
  14. Галил-Оглы Г.А., Молочков В.А., Сергеев Ю.В. (2005). Дерматоонкология. М.: Медицина для всех, 628. [Galil-Ogly GA, Molochkov VA, Sergeev JuV. (2005). Dermatoonkologija. Moscow: Medicina dlja vseh, 628 (In Russ.)]
  15. Sloane JP. (1977). The value of typing basal cell carcinomas in predicting recurrence after surgical excision. British Journal of Dermatology, 96(2);127–132.
  16. Neugut AI, Robinson E. (1992). Multiple primary neoplasms. The Cancer journal (Print),5(5),245–248.
  17. Elston DM, Stratman EJ, Miller SJ. Skin biopsy: Biopsy issues in specific diseases. J Am Acad Dermatol. 2016;74(1):1-16; quiz 17–18. doi: 10.1016/j.jaad.2015.06.033
  18. Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol. 1990;23(6 Pt 1):1118–26. doi: 10.1016/0190-9622(90)70344-h
  19. Crowson AN. (2006). Basal cell carcinoma: biology, morphology and clinical implications. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc, 19 Suppl 2, S127–S147. doi: 10.1038/modpathol.3800512
  20. Bichakjian CK, Olencki T, Aasi SZ. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Basal Skin Cancer, V.1; 2018. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf
  21. Алиев М.Д., Алиева С.Д, Алымов Ю.В., Бохян Б.Ю., Гафтон Г.И., Демидов Л.В. (2020). Клинические рекомендации. Базальноклеточный рак кожи. Ассоциация онкологов России. Электронный ресурс. URL: https://oncology-association.ru/wp-content/uploads/2020/09/bazalnokletochnyj_rak.pdf [Aliev MD, Alieva SD, Alymov JuV, Bohjan BJu, Gafton GI, Demidov LV (2020). Klinicheskie rekomendacii Bazal'nokletochnyj rak kozhi. Associacija onkologov Rossii (In Russ.)]
  22. Lott DG, Manz R, Koch C, Lorenz RR. Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation. 2010;90(6):683–687. doi: 10.1097/TP.0b013e3181ec7228
  23. Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, et al. (2012). Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology: JEADV, 26 Suppl 3, 22–31. doi: 10.1111/j.1468-3083.2012.04520.x
  24. Sartore L, Lancerotto L, Salmaso M, Giatsidis G, Paccagnella O, Alaibac M, et al. (2011). Facial basal cell carcinoma: analysis of recurrence and follow-up strategies. Oncology reports, 26(6),1423–1429. doi: 10.3892/or.2011.1453
  25. Cameron MC, Lee E, Hibler BP, Giordano CN, Barker CA, Mori S, Cordova M, Nehal KS & Rossi AM. (2019). Basal cell carcinoma: Contemporary approaches to diagnosis, treatment, and prevention. Journal of the American Academy of Dermatology, 80(2):321–339. https://doi.org/10.1016/j.jaad.2018.02.083
  26. Dunn M, Morgan MB, Beer TW. Perineural invasion: identification, significance, and a standardized definition. Dermatol Surg. 2009;35(2):214–221. doi: 10.1111/j.1524-4725.2008.34412.x
  27. Work Group; Invited Reviewers, Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018 Mar;78(3):540–559. doi: 10.1016/j.jaad.2017.10.006
  28. Goldman G. (2002). The current status of curettage and electrodesiccation. Dermatologic clinics, 20(3),569–ix. doi: 10.1016/s0733-8635(02)00022-0
  29. Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation. J Dermatol Surg Oncol. 1991;17(9):720–726. doi: 10.1111/j.1524-4725.1991.tb03425.x
  30. Adam JE. The technic of curettage surgery. J Am Acad Dermatol. 1986;15(4 Pt 1):697–702. doi: 10.1016/s0190-9622(86)70226-0
  31. Rodriguez-Vigil T, Vázquez-López F, Perez-Oliva N. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol. 2007;56(1):91–95. doi: 10.1016/j.jaad.2006.07.007
  32. Ахтямов С.Н. Электро- и радиохирургические методы в дерматологии и косметологии. Методическое пособие. 2014. 67 с. [Ahtjamov SN. Jelektro- i radiohirurgicheskie metody v dermatologii i kosmetologii. Metodicheskoe posobie. 2014. 67s. (In Russ.)] http://www.mtucimed.ru/files/Ahtyamov.pdf
  33. Kuflik EG. Cryosurgery for cutaneous malignancy. An update. Dermatol Surg. 1997;23(11):1081–1087. doi: 10.1111/j.1524-4725.1997.tb00453.x.
  34. Kuflik EG. Cryosurgery for skin cancer: 30-year experience and cure rates. Dermatol Surg. 2004;30(2 Pt 2):297–300. doi: 10.1111/j.1524-4725.2004.30090.x.
  35. Lindemalm-Lundstam B, Dalenbäck J. Prospective follow-up after curettage-cryosurgery for scalp and face skin cancers. Br J Dermatol. 2009;161(3):568–576. doi: 10.1111/j.1365-2133.2009.09310.x
  36. Paoli J, Gyllencreutz JD, Fougelberg J, Backman EJ, Modin M, Polesie S, Zaar O. Nonsurgical Options for the Treatment of Basal Cell Carcinoma. Dermatol Pract Concept. 2019;9(2):75–81. doi: 10.5826/dpc.0902a01
  37. Buckley D. Re: The freeze-thaw cycle in cryosurgery. J Eur Acad Dermatol Venereol. 2017;31(9):e405-e406. doi: 10.1111/jdv.14215
  38. Buckley D. Cryosurgery for Nonmelanoma Skin Cancer. In Modern cryosurgery for cancer. 2012;865–892.
  39. Zacarian SA. Cryosurgery of cutaneous carcinomas. An 18-year study of 3,022 patients with 4,228 carcinomas. J Am Acad Dermatol. 1983;9(6):947–56. doi: 10.1016/s0190-9622(83)70213-6
  40. Campolmi P, Brazzini B, Urso C, Ghersetich I, Mavilia L, Hercogova J, Lotti T. Superpulsed CO2 laser treatment of basal cell carcinoma with intraoperatory histopathologic and cytologic examination. Dermatol Surg. 2002;28(10):909–911; discussion 912. doi: 10.1046/j.1524-4725.2002.02076.x
  41. Kavoussi H, Ebrahimi A. Treatment and cosmetic outcome of superpulsed CO2 laser for basal cell carcinoma. Acta Dermatovenerol Alp Pannonica Adriat. 2013;22(3):57–61.
  42. Sharon E, Snast I, Lapidoth M, Kaftory R, Mimouni D, Hodak E, Levi A. Laser Treatment for Non-Melanoma Skin Cancer: A Systematic Review and Meta-Analysis. Am J Clin Dermatol. 2021;22(1):25–38. doi: 10.1007/s40257-020-00562-8
  43. Smucler R, Vlk M. Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. Lasers Surg Med. 2008;40(2):153–158. doi: 10.1002/lsm.20606
  44. Soleymani T, Abrouk M, Kelly KM. An Analysis of Laser Therapy for the Treatment of Nonmelanoma Skin Cancer. Dermatol Surg. 2017;43(5):615–624. doi: 10.1097/DSS.0000000000001048
  45. Konnikov N, Avram M, Jarell A, Tannous Z. Pulsed dye laser as a novel non-surgical treatment for basal cell carcinomas: response and follow up 12-21 months after treatment. Lasers Surg Med. 2011;43(2):72–78. doi: 10.1002/lsm.21035.
  46. Ballard CJ, Rivas MP, McLeod MP, Choudhary S, Elgart GW, Nouri K. The pulsed dye laser for the treatment of basal cell carcinoma. Lasers Med Sci. 2011;26(5):641–644. doi: 10.1007/s10103-011-0952-8
  47. Moskalik K, Kozlow A, Demin E, Boiko E. Powerful neodymium laser radiation for the treatment of facial carcinoma: 5 year follow-up data. Eur J Dermatol. 2010(6):738–742. doi: 10.1684/ejd.2010.1055
  48. Foley P, Freeman M, Menter A, Siller G, El-Azhary RA, Gebauer K, et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol. 2009;48(11):1236–1245. doi: 10.1111/j.1365-4632.2008.04022.x
  49. Oseroff A. PDT as a cytotoxic agent and biological response modifier: Implications for cancer prevention and treatment in immunosuppressed and immunocompetent patients. J Invest Dermatol. 2006;126(3):542–544. doi: 10.1038/sj.jid.5700207
  50. Filonenko E, Kaprin A, Urlova A, Grigorievykh N, Ivanova-Radkevich V. Topical 5-aminolevulinic acid-mediated photodynamic therapy for basal cell carcinoma. Photodiagnosis Photodyn Ther. 2020;30:101644. doi: 10.1016/j.pdpdt.2019.101644
  51. Schleier P, Berndt A, Kolossa S, Zenk W, Hyckel P, Schultze-Mosgau S. Comparison of aminolevulinic acid (ALA)-thermogel-PDT with methyl-ALA-thermogel-PDT in basal cell carcinoma. Photodiagnosis Photodyn Ther. 2007;4(3):197–201. doi: 10.1016/j.pdpdt.2007.04.004
  52. Basset-Seguin N, Ibbotson SH, Emtestam L, Tarstedt M, Morton C, Maroti M, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008;18(5):547–553. doi: 10.1684/ejd.2008.0472
  53. Christensen E, Skogvoll E, Viset T, Warloe T, Sundstrøm S. Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up. J Eur Acad Dermatol Venereol. 2009;23(1):58–66. doi: 10.1111/j.1468-3083.2008.02946.x
  54. Wang H, Xu Y, Shi J, Gao X, Geng L. Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed. 2015;31(1):44–53. doi: 10.1111/phpp.12148
  55. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther. 1990;48(3):381–395. doi: 10.1016/0163-7258(90)90056-8
  56. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–338. doi: 10.1038/nrc1074
  57. Moore AY. Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. J Dermatolog Treat. 2009;20(6):328–335. doi: 10.3109/09546630902789326
  58. Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial Basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg. 2007;33(4):433–439; discussion 440. doi: 10.1111/j.1524-4725.2007.33090.x
  59. Roozeboom MH, Arits AHMM, Mosterd K, Sommer A, Essers BAB, de Rooij MJM, et al. Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial. J Invest Dermatol. 2016;136(8):1568–1574. doi: 10.1016/j.jid.2016.03.043
  60. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145(12):1431–1438. doi: 10.1001/archdermatol.2009.291
  61. Jansen M, Mosterd K, Arits A, Roozeboom MH, Sommer A, Essers B, et al. Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma. The Journal of investigative dermatology.2018,138(3):527–533. doi: 10.1016/j.jid.2017.09.033
  62. Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PS, et al; Surgery versus Imiquimod for Nodular Superficial basal cell carcinoma (SINS) study group. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(1):96–105. doi: 10.1016/S1470-2045(13)70530-8
  63. Gutzmer R, Solomon JA. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma. Target Oncol. 2019;14(3):253–267. doi: 10.1007/s11523-019-00648-2
  64. ClinicalTrials.gov Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syn-Drome Patients—Full Text View. Available online: https://clinicaltrials.gov/ct2/show/NCT02762084.
  65. ClinicalTrials.gov Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas — Full Text View. Available online: https://clinicaltrials.gov/ct2/show/NCT02828111.
  66. ClinicalTrials.gov A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients with Non-Gorlin High Frequency BCC—Full Text View. Available online: https://clinicaltrials.gov/ct2/show/NCT04155190.
  67. Peris K, Licitra L, Ascierto PA, Corvò R, Simonacci M, Picciotto F, et al. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. Future oncology (London, England), 11(4):703–712. doi: 10.2217/fon.14.281
  68. Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, et al. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research, 19(9):2289–2293. doi: 10.1158/1078-0432.CCR-12-1956
  69. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD., et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC cancer. 17(1):332. doi: 10.1186/s12885-017-3286-5
  70. Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. European journal of cancer (Oxford, England: 1990),86:334–348. doi: 10.1016/j.ejca.2017.08.022
  71. Mohan SV, Chang J, Li S, Henry AS, Wood DJ, Chang AL. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma. JAMA dermatology. 152(5);527–532. doi: 10.1001/jamadermatol.2015.4330
  72. Casey D, Demko S, Shord S, Zhao H, Chen H, He K, et al. FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma. Clin Cancer Res. 2017;23(10):2377–2381. doi: 10.1158/1078-0432.CCR-16-2051
  73. Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. The Lancet. Oncology. 16(6),716–728. doi: 10.1016/S1470-2045(15)70100-2
  74. Atwood SX, Chang AL, Oro AE. Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol. 2012;199(2):193–197. doi: 10.1083/jcb.201207140
  75. Dong X, Wang C, Chen Z, Zhao W. Overcoming the resistance mechanisms of Smoothened inhibitors. Drug Discov Today. 2018;23(3):704–710. doi: 10.1016/j.drudis.2018.01.012
  76. Bendell J, Andre V, Ho A, Kudchadkar R, Migden M, Infante J, et al. Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma. Clin Cancer Res. 2018;24(9):2082–2091. doi: 10.1158/1078-0432.CCR-17-0723

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Kubanov A.A., Saytburkhanov R.R., Plakhova X.I., Kondrakhina I.N., 2021

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».